SCHEDULE: Nantahala Capital Boosts Eagle Pharma Stake to 38%

Nantahala Capital Management, LLC and its managing members disclosed a significant beneficial ownership of 38.08% in Eagle Pharmaceuticals, Inc.

Summary

• Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, reported beneficial ownership of 4,945,209 shares of Eagle Pharmaceuticals, Inc. common stock.
• This represents 38.08% of the total outstanding shares of Eagle Pharmaceuticals, Inc.
• The shares are held by funds and separately managed accounts under Nantahala's control.
• Nantahala Capital Partners Limited Partnership and Blackwell Partners LLC Series A, both advised by Nantahala, each hold more than 5% of the outstanding shares.
• The reporting persons share both voting and dispositive power over all 4,945,209 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, except for activities solely related to nominations under Rule 14a-11.

Sentiment

Score: 7

Explanation: The disclosure of a substantial 38.08% stake by a prominent investment firm like Nantahala Capital Management is generally viewed positively, indicating strong investor confidence in the company's long-term prospects. While the filing states the investment is not for control, the sheer size of the stake suggests a significant commitment.

Positives

• A significant stake of 38.08% held by Nantahala Capital Management, a reputable investment firm, indicates strong conviction in Eagle Pharmaceuticals, Inc.'s long-term prospects.
• The investment is stated to be in the ordinary course of business, suggesting a long-term investment horizon rather than an immediate activist play for control (though Rule 14a-11 nominations are allowed).

Risks

• The filing states the investment is not for the purpose of changing or influencing control, which might limit immediate activist pressure for strategic changes, though nominations under Rule 14a-11 are permitted.

Stakeholder Impact

• Shareholders: The large institutional ownership could provide stability and potentially signal confidence to other investors. It also means a significant portion of the company's shares are concentrated.

Key Dates

Recommendation

The filing indicates a significant and concentrated ownership by Nantahala Capital Management, LLC, holding 38.08% of Eagle Pharmaceuticals, Inc. This substantial stake by a sophisticated institutional investor suggests a strong long-term conviction in the company's value. While the filing itself does not provide operational or financial performance updates, the sheer size of this position implies a belief in the company's future prospects. For existing investors, maintaining a 'hold' position aligns with the implied confidence from a major shareholder. For potential new investors, this disclosure might warrant further due diligence into Eagle Pharmaceuticals, Inc., considering the significant institutional backing.

Keywords

Eagle Pharmaceuticals, Nantahala Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Pharmaceuticals, Common Stock, Investment Management